Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 9/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | TP53 | P04637 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532195 | 0.90 | LMNA (0.67) | LMNAKMT2AMAPTTP53MEN1 | |
| SCHEMBL15612975 | 0.89 | HTR2B (0.67) | LMNAKMT2AMAPTTP53MEN1 | |
| SCHEMBL14485376 | 0.88 | LMNA (0.65) | LMNAKMT2AMAPTTP53MEN1 | |
| SCHEMBL23677234 | 0.87 | LMNA (0.61) | LMNAKMT2AMAPTTP53MEN1 | |
| SCHEMBL15612807 | 0.87 | HTR2B (0.65) | LMNAKMT2AMAPTTP53MEN1 | |
| SCHEMBL1001410 | 0.86 | LMNA (0.68) | LMNAKMT2AMAPTTP53ALDH1A1 | |
| SCHEMBL15613061 | 0.85 | HTR2B (0.62) | LMNAKMT2AMAPTTP53MEN1 | |
| SCHEMBL15076366 | 0.85 | TP53 (0.60) | LMNAKMT2AMAPTTP53ALDH1A1 | |
| SCHEMBL17115694 | 0.84 | LMNA (0.58) | LMNAKMT2AMAPTTP53ALDH1A1 | |
| SCHEMBL15613065 | 0.83 | MAPT (0.71) | LMNAKMT2AMAPTTP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336178-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | claimed |
| US-20130203733-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-08-08 | — | — | US | claimed |
| US-20050239833-A1 | Compositions and methods for modulating interaction between polypeptides | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2005-10-27 | — | — | US | claimed |
| WO-2005087217-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | THE GENERAL HOSPITAL CORPORATION (US) | 2005-09-22 | — | — | WO | claimed |
| US-20140336178-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336178-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-20130203733-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203733-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-08-08 | — | — | US | disclosed |
| US-8404747-B2 | Compositions and methods for modulating interaction between polypeptides | THE GENERAL HOSPITAL CORPORATION (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404747-B2 | Compositions and methods for modulating interaction between polypeptides | THE GENERAL HOSPITAL CORPORATION (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404747-B2 | Compositions and methods for modulating interaction between polypeptides | THE GENERAL HOSPITAL CORPORATION (US) | 2013-03-26 | — | — | US | disclosed |
| US-20050239833-A1 | Compositions and methods for modulating interaction between polypeptides | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2005-10-27 | — | — | US | disclosed |
| WO-2005087217-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | THE GENERAL HOSPITAL CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239833-A1 | Compositions and methods for modulating interaction between polypeptides | IAPP, SERPINA6, SERPINA2 | LMNA 1941/4885KMT2A 4744/4885MAPT 2215/4885 |
| US-20130203733-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | IAPP, SERPINA6, SERPINA2 | LMNA 1941/4885KMT2A 4744/4885MAPT 2215/4885 |
| US-20140336178-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | IAPP, SERPINA6, SERPINA2 | LMNA 1941/4885KMT2A 4744/4885MAPT 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.